EGFR-TKI对比化疗一线治疗晚期EGFR基因突变的非小细胞肺癌Ⅲ期临床试验meta分析.pdfVIP

关键词 tH,细胞肺癌；EGFR-TKI；一线治疗；Meta分析 2 ·英文论著摘要· VS asfirst--linetreatmentof EGFR-TKI chemotherapy advancednon··smallcell cancerwithmutated lung EGFR：Metaof IIItrials Analysisphase Objective review and ofEGFR-TKI、)vitll Systematicefficacysafety standard inthefirst-linetreatmentofEGFRmutationsinadvanced chemotherapy non-smallcell lungcancer(NSCLC)． Methods ElectronicsearchesofMedline 966-201 Cochrane (1 2)，the Library, theinclusioncriteriaof EMbase(1974-2012)，CNKI(1978—2012)，after controlled witllStata．11．0software． trials(RCT)performmeta—analysis Results Sevenrandomizedcontroledtiralsof3013 wereincludedinthis patients anlysis． Theresultsof showedthat：EGFR-TKIcan meta-analyses significantly prolong progression-freesurvival(PFS)HR=0．39，95％Ch Overall survival Rate(ORR)RR=2．10，95％Ch1．62-2．71，P0．001，overall Response no differenceHIPO．97，95％CI：0．80-1．18，P=0．78．The (os)wassignificant major forEGFR-TKlwererashand adverseevent diarrhea(rashRR=4．03，95％Ch2．61·6．24， commonadverseevent for